

		<b>EMLc</b>	ATC codes: <b>L01CB01</b>
<b>Indication</b>	Malignant neoplasms of kidney, except renal pelvis	ICD11 code: <b>2D40.Z</b>	
<b>INN</b>	Etoposide		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Formulations</b>	Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule ; 50 mg capsule		
<b>EML status history</b>	First added in 2021 ( <a href="#">TRS 1035</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Tags</b>	<a href="#">Cancer</a>		
<b>Wikipedia</b>	<a href="#">Etoposide</a> 		
<b>DrugBank</b>	<a href="#">Etoposide</a> 		

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.

